DCM Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

DCM Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-35,000	Closed	-$654K	–	300
2020 Q4	$654K	Buy	+35,000	New	+$654K	0.38%	88

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM Advisors's VIVO Position: Q1 2021 in Review

DCM Advisors sold out of Meridian Bioscience Inc (VIVO) in Q1 2021, closing a stake of 35,000 shares — an estimated $654K sold.

DCM Advisors first reported a position in VIVO in Q4 2020 and held it in 1 quarter. The position peaked at $654K in Q4 2020. 215 funds tracked by Wall St. Rank hold VIVO as of Q1 2021.

DCM Advisors reported no remaining Meridian Bioscience Inc position as of Q1 2021 after selling out during the quarter.
DCM Advisors sold 35,000 Meridian Bioscience Inc shares in Q1 2021, an estimated $654K.
DCM Advisors first reported a position in Meridian Bioscience Inc in Q4 2020 and held it in 1 quarter.
DCM Advisors's Meridian Bioscience Inc position peaked at $654K in Q4 2020.
215 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2021.

Based on DCM Advisors's 13F filing for Q1 2021, filed 17 May 2021.